Cite
HARVARD Citation
Armstrong, A. et al. (2017). Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current medical research and opinion. pp. 1133-1139. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Armstrong, A. et al. (2017). Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current medical research and opinion. pp. 1133-1139. [Online].